FreeCME

Monoclonal Antibodies in the Treatment of at Risk Patients With COVID-19 to Reduce Hospitalization and Severe Disease

CME: 1.0

November 30, 2021
/ Print / Reprints /
| Share More
/ Text Size+


Target Audience

This activity is designed to meet the educational needs of pulmonologists, infectious disease specialists, primary care providers, and other health care providers who may be involved in the management of patients with COVID-19.

Program Overview

Providers managing patients with COVID-19 are not knowledgeable about the latest evidence-based monoclonal antibody treatments available. Methods for delivering these treatments are also discussed.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the utility of administering monoclonal antibodies for the management of at-risk patients with COVID-19, including variants
  • Explain how management of COVID-19 with monoclonal antibodies affects viral load
  • Recognize specific IDSA and NIH guideline-recommended treatments for at-risk patients and select appropriate monoclonal antibody therapy for patients with COVID-19, including combination therapy
  • Describe the use of monoclonal antibodies in immunosuppressed patients with COVID-19
  • Discuss the safety and efficacy of the available and emerging monoclonal antibodies for the management of at-risk patients with COVID-19

Post a comment to this article